A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Liver Diseases
Hypertension, Portal

Interventions

DRUG: Avenciguat
DRUG: Empagliflozin

Sponsor

Boehringer Ingelheim